(PharmaNewsWire.Com, February 14, 2019 ) The Business Research Company’s Musculoskeletal Disorders Drugs global market report, covers the year-on-year growth of the global Musculoskeletal Disorders Drugs market historic and forecast growth. It also includes chapters on the Musculoskeletal Disorders Drugs market trends, geographical analysis, and competitive landscape.
The global musculoskeletal disorders drugs market size is expected to reach $170 billion by 2022, significantly growing at a CAGR of around 8% during the forecast period.
Musculoskeletal Disorders Drugs Market Trends
The musculoskeletal disorders drugs market consists of sales of musculoskeletal disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce musculoskeletal disorders drugs to treat musculoskeletal disorders such as arthritis, osteoporosis, osteocalcin, and other disorders. This industry includes establishments that produce drugs to treat rheumatoid arthritis, muscle relaxants to reduce muscle pain, and other drugs used in treating osteoarthritis, analgesics drugs, immunosuppressive.
Introduction of advanced pain free drug delivery technologies is promoting the use of musculoskeletal drugs. Drug delivery systems refer to methods or processes used to administer a pharmaceutical compound to achieve a therapeutic effect in humans or animals. Drug delivery products such as intrathecal pumps are being used to deliver muscle relaxants such as baclofen directly into spinal cord to provide instant relief. Intra-Articular drug delivery systems are also widely being used to administer medicines to treat arthritis. In addition, these products reduce spasticity symptoms and lower the side effects caused by oral spasticity medications.
The growth in the metabolic disorders drugs market is due to increase in healthcare awareness, number of surgical operations and prevalence of musculoskeletal disorders such as fibromyalgia, rheumatoid arthritis, osteoarthritis around the world
The global Musculoskeletal Disorders Drugs market report covers the following regions under the geographical analysis section: Asia Pacific, Western Europe, North America, Middle East, Africa, South America, and Eastern Europe. Major countries under each of these regions are also covered under the country analysis chapters.
With rapid growth due to growing diabetic population worldwide, and increasing academia-industry collaborations to develop new drugs for treatment of metabolic disorders, the global Musculoskeletal Disorders Drugs market is expected to increase in potential and scope. TBRC’s report also covers the Musculoskeletal Disorders Drugs drivers and restraints in the market.
The global Musculoskeletal Disorders Drugs market’s segment shares in each geographic region are mentioned in the report, along with the historic and forecast growth rates for each segment presented visually with supporting reasons to justify the growth rates.
The top companies included in the global Musculoskeletal Disorders Drugs market report are F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Pfizer Inc., Abbott Laboratories Inc., and Daiichi Sankyo Company.
About The Business Research Company:
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
